Identification of a Primary Target of Thalidomide Teratogenicity

Integrated Research Institute, Tokyo Institute of Technology, Yokohama 226-8503, Japan.
Science (Impact Factor: 33.61). 03/2010; 327(5971):1345-50. DOI: 10.1126/science.1177319
Source: PubMed


Half a century ago, thalidomide was widely prescribed to pregnant women as a sedative but was found to be teratogenic, causing multiple birth defects. Today, thalidomide is still used in the treatment of leprosy and multiple myeloma, although how it causes limb malformation and other developmental defects is unknown. Here, we identified cereblon (CRBN) as a thalidomide-binding protein. CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks. Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the associated ubiquitin ligase activity. This study reveals a basis for thalidomide teratogenicity and may contribute to the development of new thalidomide derivatives without teratogenic activity.

Download full-text


Available from: Hiroshi Handa,

Click to see the full-text of:

Article: Identification of a Primary Target of Thalidomide Teratogenicity

0 B

See full-text
  • Source
    • "Although many of the effects of the drug have been documented, there is still a lot more information about its mechanism of action required (Strasser & Ludwig, 2002). Recently, there has been research with zebrafish in Japan that has isolated the protein that caused the birth defects in the children of Thalidomide patients (Ito et al., 2010). The Cytochrome P450 enzyme responsible for Thalidomide metabolism is 2C19 (Ando et al., 2002) and this is found in the liver and is subject to polymorphisms. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Cytochrome P450 (CYP) system is involved in 90% of the human body's interactions with xenobi-otics and due to this, it has become an area of avid research including the creation of transgenic mice. This paper proposes a three-compartment model which is used to explain the drug metabolism in the Hepatic Reductase Null (HRN) mouse developed by the University. (2003) Inactivation of the hepatic cytochrome p450 system by conditional deletion of hepatic cytochrome p450 reductase. J. Biol. Chem. 278, 13480–13486). The model is compared with a two-compartment model using experimental data from studies using wild-type and HRN mice. This comparison allowed for metabolic differences between the two types of mice to be isolated. The three sets of drug data (Gefitinib, Midazolam and Thalidomide) showed that the transgenic mouse has a decreased rate of metabolism.
    Mathematical Medicine and Biology 10/2015; DOI:10.1093/imammb/dqv029 · 1.66 Impact Factor
  • Source
    • "Indeed, contrary to etoposide and camptothecin , doxorubicin is also a strong DNA intercalator, inducing KAT5-dependent histone acetylation and release from open chromatin (histone eviction) (Choi et al., 2009; Ikura et al., 2000), leading to cell-cycle arrest (Pang et al., 2013). Similarly, DeMAND identified SIK1 as a doxorubicin-specific effector (ranked 36 th ), which is required for cardiac progenitor cell maintenance (CPCs) (Romito et al., 2010), thus pinpointing the compound's key adverse event, i.e., cardiomyopathy followed by congestive heart failure (Zhang et al., 2012b). Both KAT5 and SIK1 were completely missed by t test analysis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Genome-wide identification of the mechanism of action (MoA) of small-molecule compounds characterizing their targets, effectors, and activity modulators represents a highly relevant yet elusive goal, with critical implications for assessment of compound efficacy and toxicity. Current approaches are labor intensive and mostly limited to elucidating high-affinity binding target proteins. We introduce a regulatory network-based approach that elucidates genome-wide MoA proteins based on the assessment of the global dysregulation of their molecular interactions following compound perturbation. Analysis of cellular perturbation profiles identified established MoA proteins for 70% of the tested compounds and elucidated novel proteins that were experimentally validated. Finally, unknown-MoA compound analysis revealed altretamine, an anticancer drug, as an inhibitor of glutathione peroxidase 4 lipid repair activity, which was experimentally confirmed, thus revealing unexpected similarity to the activity of sulfasalazine. This suggests that regulatory network analysis can provide valuable mechanistic insight into the elucidation of small-molecule MoA and compound similarity. Copyright © 2015 Elsevier Inc. All rights reserved.
    Cell 07/2015; 162(2):441-451. DOI:10.1016/j.cell.2015.05.056 · 32.24 Impact Factor
    • "This robust accumulation of BRD4, together with the reversible nature of inhibitor binding to BRD4, may in part account for the modest effect of these inhibitors on downstream c-MYC suppression and cell proliferation inhibition. To circumvent these limitations, we designed a hetero-bifunctional molecule , ARV-825, by connecting a small-molecule BRD4 binding moiety (OTX015) to an E3 ligase cereblon binding moiety (pomalidomide ) using PROTAC technology (Boi et al., 2015; Fischer et al., 2014; Ito et al., 2010). OTX015 is currently in phase I clinical trials and pomalidomide is a potent third-generation immunomodulatory drug (IMiD), which functions through interacting with the E3 ligase cereblon and inducing degradation of essential Ikaros transcription factors in MM (Boi et al., 2015; Lu et al., 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathological settings, particularly cancer. While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt's lymphoma (BL), we show that BRD4 inhibitors lead to robust BRD4 protein accumulation, which may account for their limited suppression of MYC expression, modest antiproliferative activity, and lack of apoptotic induction. To address these limitations we designed ARV-825, a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 in all BL cell lines tested. Consequently, ARV-825 more effectively suppresses c-MYC levels and downstream signaling than small-molecule BRD4 inhibitors, resulting in more effective cell proliferation inhibition and apoptosis induction in BL. Our findings provide strong evidence that cereblon-based PROTACs provide a better and more efficient strategy in targeting BRD4 than traditional small-molecule inhibitors. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Chemistry & biology 06/2015; 22(6). DOI:10.1016/j.chembiol.2015.05.009 · 6.65 Impact Factor
Show more